THIS WEBSITE USES COOKIES

We use cookies to personalize content and ads, provide social media features, and analyze traffic to our website. We also share information about your use of our website with our social media, advertising and analytics partners. Our partners may combine this information with other data that you have provided to them or that they have collected in the course of your use of the Services.

Cancer

Photo credits: pixabay.com

Commented by Mario Hose on August 2nd, 2022 | 10:57 CEST

Defence Therapeutics VP Research + Development Dr. Moutih Rafei on the next generation oncology-targeting therapies

Expert
Biotech
Cancer
DefenceTherapeutics

The publicly traded biotechnology company called Defence Therapeutics is developing new vaccines and ADC products on its own proprietary platform. The Accum technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency.

Read